Novavax (NVAX) is a Top-Ranked Momentum Stock: Should You Buy?

Core Insights - The Zacks Premium service provides tools for investors to enhance their stock market strategies and confidence [1] - Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] - Value Score identifies undervalued stocks using financial ratios [3] - Growth Score assesses a company's financial health and future growth potential [4] - Momentum Score capitalizes on price trends and earnings outlook changes [5] - VGM Score combines all three styles to provide a comprehensive evaluation of stocks [6] Zacks Rank and Performance - The Zacks Rank is a proprietary model that utilizes earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41%, significantly outperforming the S&P 500 [8] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock Highlight: Novavax (NVAX) - Novavax, Inc. is a biotechnology company focused on developing vaccines for infectious diseases and has a Zacks Rank of 3 (Hold) with a VGM Score of B [12] - The company has a Momentum Style Score of B, with shares increasing by 16.3% in the past four weeks [13] - Recent upward revisions in earnings estimates indicate a positive outlook, with the Zacks Consensus Estimate rising from $1.05 to $2.03 per share [13] - Novavax has an impressive average earnings surprise of 77.9%, making it a noteworthy consideration for investors [13]